# US 2019/0314528 A1 · Targeted therapeutics

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314528 A1
- Document ID: US20190314528A1
- Status: Published application
- Kind: A1
- Application number: 16/454,586
- Filed: 2019-06-27
- Published: 2019-10-17
- Earliest claimed: 2013-10-28
- Assignees: Madrigal Pharmaceuticals, Inc.
- Applicants: Madrigal Pharmaceuticals, Inc.
- Inventors: Dinesh U. Chimmanamada; Weiwen Ying
- Web page: https://patentgrep.com/patent/US20190314528A1

## CPC

- A61K 49/00: Preparations for testing in vivo
- A61K 47/545: {Heterocyclic compounds (A61K47/558 takes precedence)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.

## Claims

### Claim 1

A binding moiety-drug conjugate (SDC-TRAP) comprising a binding moiety and an effector moiety,
wherein the binding moiety binds to Hsp90,
wherein the effector moiety is a cytotoxic agent selected from the group consisting of LY2801653, LY2835219, LY2606368, LY2874455, LY2090314, LY2940680, LY2784544, LY2228820, LY2157299, LY2603618, LY353381, trimetrexate, and a derivative thereof, and
wherein the binding moiety and the effector moiety are covalently attached.

### Claim 2 (depends on 1)

The SDC-TRAP of claim 1, wherein the binding moiety is an Hsp90 ligand or a prodrug thereof.

### Claim 3 (depends on 2)

The SDC-TRAP of claim 2, wherein the Hsp90 ligand is an Hsp90 inhibitor.

### Claim 4 (depends on 3)

The SDC-TRAP of claim 3, wherein the Hsp90 inhibitor is selected from the group consisting of ganetespib, geldanamycins, macbecins, tripterins, tanespimycins, radicicols, and a derivative thereof.

### Claim 5 (depends on 1)

The SDC-TRAP of claim 1, wherein the binding moiety and the effector moiety are covalently attached by a linker.

### Claim 6 (depends on 1)

A pharmaceutical composition comprising a therapeutically effective amount of at least one SDC-TRAP of claim 1, and at least one pharmaceutical excipient.

### Claim 7 (depends on 1)

A kit for imaging, diagnosing, and/or selecting a subject comprising at least one SDC-TRAP of claim 1 and instruction for administering an effective amount of at least one SDC-TRAP of claim 1 to the subject, thereby imaging, diagnosing, and/or selecting the subject.

### Claim 8 (depends on 1)

A method for treating a subject having a cancer comprising administering a therapeutically effective amount of at least one SDC-TRAP to the subject, thereby treating the cancer,
wherein the SDC-TRAP comprises the SDC-TRAP of claim 1.

### Claim 9 (depends on 1)

A method for treating a subject having chronic bronchitis comprising administering a therapeutically effective amount of at least one SDC-TRAP to the subject, thereby treating the chronic bronchitis,
wherein the SDC-TRAP comprises the SDC-TRAP of claim 1.

### Claim 10 (depends on 1)

A method for treating a subject having asthma comprising administering a therapeutically effective amount of at least one SDC-TRAP to the subject, thereby treating the asthma,
wherein the SDC-TRAP comprises the SDC-TRAP of claim 1.

### Claim 11 (depends on 1)

A method for treating a subject having actinic keratosis comprising administering a therapeutically effective amount of at least one SDC-TRAP to the subject, thereby treating the actinic keratosis,
wherein the SDC-TRAP comprises the SDC-TRAP of claim 1.
